IC
CRBP icon

Ikarian Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Ikarian Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-233,100
Closed -$4.81M – 184
2024
Q3 		$4.81M Buy
+233,100
New +$11.9M 0.67% 43
2020
Q3 		– Sell
-45,000
Closed -$11.3M – 188
2020
Q2 		$11.3M Buy
+45,000
New +$9.09M 0.9% 35

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital's CRBP Position: Q1 2025 in Review

Ikarian Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 51,431 shares — an estimated $607K sold.

Ikarian Capital first reported a position in CRBP in Q4 2020 and held it in 17 quarters. The position peaked at $21.9M in Q1 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Ikarian Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 51,431 Corbus Pharmaceuticals shares in Q1 2025, an estimated $607K.
  • Ikarian Capital first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Ikarian Capital's Corbus Pharmaceuticals position peaked at $21.9M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.